Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BOLT

Bolt Biotherapeutics Inc

Jun 13 • 04:00PM ET

6.10

Dollar change -0.13
Percentage change -2.09	%

Healthcare • Biotechnology • USA • NASD

Peers: APLS IOVA FATE FOLD TGTX TVRD ANAB CTMX CLPT XBIT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-33.14	Insider Own	34.20%	Shs Outstand	1.92M	Perf Week	-5.57%
Market Cap	11.69M	Forward P/E	-	EPS next Y	-19.72	Insider Trans	1.55%	Shs Float	1.26M	Perf Month	-12.86%
Income	-63.35M	PEG	-	EPS next Q	-6.32	Inst Own	19.08%	Short Float	1.71%	Perf Quarter	-26.33%
Sales	3.64M	P/S	3.21	EPS this Y	24.73%	Inst Trans	-3.68%	Short Ratio	1.10	Perf Half Y	-46.59%
Book/sh	24.42	P/B	0.25	EPS next Y	20.61%	ROA	-55.38%	Short Interest	0.02M	Perf Year	-59.80%
Cash/sh	20.67	P/C	0.30	EPS next 5Y	24.06%	ROE	-83.92%	52W Range	5.20 - 15.60	Perf YTD	-43.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.73%	ROIC	-91.65%	52W High	-60.90%	Beta	0.92
Dividend TTM	-	Quick Ratio	3.13	Sales past 5Y	104.50%	Gross Margin	52.67%	52W Low	17.31%	ATR (14)	0.65
Dividend Ex-Date	-	Current Ratio	3.13	EPS Y/Y TTM	0.40%	Oper. Margin	-1738.84%	RSI (14)	44.27	Volatility	5.51% 5.45%
Employees	52	Debt/Eq	0.53	Sales Y/Y TTM	-67.87%	Profit Margin	-1741.26%	Recom	2.60	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.48	EPS Q/Q	-1.39%	Payout	-	Rel Volume	0.57	Prev Close	6.23
Sales Surprise	61.36%	EPS Surprise	18.31%	Sales Q/Q	-76.83%	Earnings	May 12 AMC	Avg Volume	19.63K	Price	6.10
SMA20	-3.18%	SMA50	-9.71%	SMA200	-39.30%	Trades		Volume	11,148	Change	-2.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-21	Initiated	SVB Leerink	Outperform	$36
Mar-02-21	Initiated	Stifel	Buy	$40
Mar-02-21	Initiated	Morgan Stanley	Overweight	$45
Mar-02-21	Initiated	Guggenheim	Buy	$42

May-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.70%
05:10PM	Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:28PM	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
05:50PM	Loading…
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates (GlobeNewswire)
Apr-30-25 04:05PM	Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-25-25 01:00PM	Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 (GlobeNewswire)
Mar-25-25 04:30PM	Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 (GlobeNewswire)
Mar-24-25 04:37PM	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:20PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 04:05PM	Bolt Biotherapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-11-25 04:05PM	Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. (GlobeNewswire)
Nov-12-24 05:35PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Loading…
04:27PM	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-24 10:00AM	Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting (GlobeNewswire)
Sep-04-24 04:05PM	Bolt Biotherapeutics Announces Changes to its Board of Directors (GlobeNewswire)
Aug-28-24 07:00AM	Bolt Biotherapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-24-24 06:13AM	The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows (InvestorPlace)
May-15-24 03:00PM	Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ... (GuruFocus.com) -37.12%
01:34PM	Top Midday Decliners (MT Newswires)
08:05AM	Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate (BioPharma Dive)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-14-24 10:54PM	BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team (GlobeNewswire)
Mar-21-24 10:53PM	BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Feb-27-24 07:00AM	Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Dec-21-23 07:30AM	Pacira Appoints Frank D. Lee as Chief Executive Officer (GlobeNewswire)
Dec-05-23 07:00AM	Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu (GlobeNewswire)
Nov-09-23 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 07:00AM	Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-23-23 10:30AM	Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress (GlobeNewswire) -7.80%
Oct-18-23 07:00AM	Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meeting (GlobeNewswire)
Oct-17-23 07:00AM	Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers (GlobeNewswire)
Oct-16-23 07:00AM	Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 (GlobeNewswire) +6.25%
Sep-28-23 07:00AM	Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers (GlobeNewswire)
Sep-12-23 08:05AM	Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042 (GlobeNewswire)
Sep-05-23 04:15PM	Bolt Biotherapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-09-23 06:10AM	Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations (Simply Wall St.)
Aug-07-23 04:10PM	Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer (GlobeNewswire)
Jul-31-23 05:27PM	Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-13-23 11:22AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-30-23 08:00AM	BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases (PR Newswire) -6.56%
May-25-23 05:05PM	Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
May-11-23 04:05PM	Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +12.50%
Apr-26-23 10:00AM	Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-11-23 07:41AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year (Simply Wall St.)
Mar-30-23 01:16PM	Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies (Benzinga)
Mar-29-23 04:15PM	Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
04:05PM	Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies (GlobeNewswire)
Mar-14-23 04:30PM	Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting (GlobeNewswire) +7.86%
Feb-28-23 08:00AM	Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Bolt Biotherapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-04-23 09:31AM	Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation (Simply Wall St.)
Dec-14-22 04:43PM	Bolt Biotherapeutics Appoints Laura Berner to Board of Directors (GlobeNewswire)
Nov-10-22 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 08:00AM	Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting (GlobeNewswire)
Nov-02-22 07:20AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year (Simply Wall St.)
Nov-01-22 10:01AM	Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference (GlobeNewswire)
Sep-09-22 12:08PM	16 Best Penny Stocks to Buy Now (Insider Monkey)
Aug-31-22 07:30AM	Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-22 12:23PM	Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead? (Zacks)
12:02PM	J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli (Zacks)
Aug-10-22 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +10.53% -6.35%
Jul-22-22 08:44AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -5.75%
Jun-10-22 07:21AM	Zacks.com featured highlights include Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery (Zacks) -6.57%
May-27-22 08:00AM	Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022 (GlobeNewswire)
May-26-22 06:52AM	The past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable (Simply Wall St.)
May-13-22 08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 04:05PM	Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +5.41%
May-11-22 07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks) -10.30%
Apr-07-22 08:00AM	Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference (GlobeNewswire)
Mar-30-22 04:05PM	Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-08-22 04:30PM	Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022 (GlobeNewswire) +15.20%
Feb-12-22 06:30AM	Companies Like Bolt Biotherapeutics (NASDAQ:BOLT) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-02-22 08:00AM	Bolt Biotherapeutics to Participate in Upcoming February Conferences (GlobeNewswire)
Jan-27-22 01:43PM	7 Little-Known Penny Stocks That Could Take Off Any Moment (InvestorPlace) -12.40%
Jan-06-22 08:00AM	Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors (GlobeNewswire) -10.95%
Dec-17-21 06:14AM	3 Biotech Stocks That Sank: Are Any a Bad-News Buy? (Motley Fool) +5.32%
Dec-16-21 08:00AM	Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors (GlobeNewswire)
Dec-06-21 04:29PM	Why Bolt Biotherapeutics Stock Crashed Today (Motley Fool) -55.81%
09:23AM	Bolt Biotherapeutics Stock Halves on Mediocre Trial Data (Investing.com)
06:00AM	Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021 (GlobeNewswire)
Dec-02-21 06:00AM	Bolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021 (GlobeNewswire)
Nov-19-21 08:00AM	Bolt Biotherapeutics Announces Changes to its Board of Directors (GlobeNewswire)
Nov-12-21 07:00AM	Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-09-21 04:05AM	Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights (GlobeNewswire) -7.42%
Nov-08-21 08:00AM	Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference (GlobeNewswire)
Nov-03-21 08:00AM	89bio Announces Appointment of Kathy LaPorte to its Board of Directors (GlobeNewswire)
Oct-01-21 08:00AM	Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC) (GlobeNewswire) +5.77%
Sep-08-21 07:30AM	Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Study BDC-1001 in Combination with Opdivo® for Treatment of HER2-Expressing Solid Tumors (GlobeNewswire) -6.38%
Sep-02-21 08:00AM	Bolt Biotherapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) +5.07%
Aug-27-21 05:55AM	Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates (Benzinga) +9.71%

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nemec Sarah	Senior VP, Finance and PAO	Dec 16 '24	Buy	0.50	2,500	1,241	16,633	May 05 08:40 PM
Quinn William P.	President, CEO and CFO	Dec 16 '24	Buy	0.50	2,500	1,241	41,272	May 05 08:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BOLT

Bolt Biotherapeutics Inc

Upgrade your FINVIZ experience